Back to Search
Start Over
The impact of peroxisome proliferator‐activated receptor‐γ activating angiotensin receptor blocker on outcomes of patients receiving immunotherapy.
- Source :
-
Cancer Medicine . Apr2023, Vol. 12 Issue 8, p9583-9588. 6p. - Publication Year :
- 2023
-
Abstract
- Background: Certain angiotensin receptor blockers (ARBs) have peroxisome proliferator‐activated receptor‐γ (PPAR‐γ) activation property, which has been associated with improved programmed cell death ligand 1 blockade and cytotoxic T lymphocyte‐mediated antitumor activity. Methods: We conducted a retrospective cohort study to investigate the impact of PPAR‐γ‐activating ARBs on patient survival in patients treated with immune checkpoint inhibitors (ICIs) across all types of cancers. Results: A total of 167 patients receiving both angiotensin receptor blockers (ARBs) and immune checkpoint inhibitors (ICIs) were included. Compared with non‐PPAR‐γ‐ARB users (n = 102), PPAR‐γ‐ARB users (n = 65) had a longer median overall survival (not reached [IQR, 16.0—not reached] vs. 18.6 [IQR, 6.1–38.6] months) and progression‐free survival (17.3 [IQR, 5.1—not reached] vs. 8.2 [IQR, 2.4–18.6] months). In Cox regression analysis, the use of PPAR‐γ‐activating ARBs had an approximately 50% reduction in all‐cause mortality and disease progression. Patients who received PPAR‐γ‐activating ARBs also had higher clinical benefit rates than non‐PPAR‐γ‐ARB users (82% vs. 61%, p = 0.005). Conclusion: The use of ARBs with PPAR‐γ‐activating property is linked with better survival among patients receiving ICIs. [ABSTRACT FROM AUTHOR]
Details
- Language :
- English
- ISSN :
- 20457634
- Volume :
- 12
- Issue :
- 8
- Database :
- Academic Search Index
- Journal :
- Cancer Medicine
- Publication Type :
- Academic Journal
- Accession number :
- 163604701
- Full Text :
- https://doi.org/10.1002/cam4.5734